Notice of Intent to Publish a Funding Opportunity Announcement for Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional)
ID: 356190Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356190
Timeline
    Description

    The National Institutes of Health (NIH) is planning to publish a Notice of Funding Opportunity Announcement for the Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers, with a focus on supporting the Complement Animal Research In Experimentation program. This initiative aims to foster collaborations and innovative projects that enhance research methodologies in health-related fields, utilizing the UM1 activity code, which allows for optional clinical trials. The total estimated program funding is $18 million, with an award ceiling of $2 million per award, and the NIH anticipates making approximately four awards. Interested applicants should note that the synopsis is expected to be posted on October 18, 2024, with proposals due by February 28, 2025, and awards anticipated to be made by December 1, 2025.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Complement-ARIE New Approach Methodologies (NAMs) Data Hub and Coordinating Center (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is planning to publish a Notice of Funding Opportunity Announcement (NOFO) for the Complement-ARIE New Approach Methodologies (NAMs) Data Hub and Coordinating Center, which will be available under the U24 activity code. This initiative aims to support the Complement Animal Research In Experimentation (Complement-ARIE) program, encouraging the research community to form collaborations and develop responsive projects. The funding opportunity is significant for advancing health-related research methodologies, with an estimated total program funding of $5 million and a single award anticipated. Interested applicants should note that the synopsis is expected to be posted on November 29, 2024, with a closing date of March 10, 2025, and an estimated award date of December 1, 2025.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the establishment of Animal and Biological Material Resource Centers under the Notice of Funding Opportunity (NOFO) RFA-OD-25-011. This initiative aims to support the creation, preservation, and distribution of high-quality laboratory animals and biological materials, while also integrating new approach methodologies (NAMs) that complement traditional animal-based research. The program is crucial for enhancing research infrastructure and ensuring the availability of resources that facilitate scientific rigor and reproducibility in biomedical research. A total funding amount of $1.3 million is anticipated to support at least two awards annually from FY 2023-2025, with applications due by January 9, 2029. Interested applicants can reach out to the Office of Research Infrastructure Programs at ORIPDCM@mail.nih.gov for further information.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Informatics, Coordination and Service Center (ICSC) within the Mutant Mouse Resource and Research Centers (MMRRC) consortium, aimed at enhancing biomedical research through improved informatics services. The initiative seeks to support projects that develop and assist resources related to animal and biological materials, focusing on the integration of new approach methodologies (NAMs) alongside traditional animal-based research. This funding opportunity, utilizing the U42 activity code, is expected to provide a total of $878,000, with one award anticipated, and applications will be accepted starting in Summer 2025, following the NOFO publication in Spring 2025. For further inquiries, interested applicants can contact Dr. Oleg Mirochnitchenko at oleg.mirochnitchenko@nih.gov or by phone at 301-425-0479.
    Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)" aimed at supporting the development, production, and distribution of nonhuman primate-specific immunologic reagents. This initiative, led by the National Institute of Allergy and Infectious Diseases (NIAID), seeks to enhance preclinical research in nonhuman primate models to accelerate advancements in cures, vaccines, and treatments for immune-mediated diseases and emerging infectious diseases. The estimated total program funding is $1,300,000, with one award expected, and applications are anticipated to be solicited starting in late August 2025, with a closing date in late October 2025. Interested applicants can reach out to Dr. Shilpa Kulkarni at shilpa.kulkarni@nih.gov or call 240-747-7365 for further information.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the Animal and Biological Material Resource Centers under the P40 grant mechanism, aimed at supporting projects that develop and maintain animal models and related biological resources. This initiative seeks to enhance the scientific rigor and reproducibility of biomedical research by providing accessible resources, including special colonies of laboratory animals, informatics tools, and new approach methodologies (NAMs) that complement traditional animal-based research. With an estimated total program funding of $1,300,000 and the expectation of awarding two grants, interested small businesses should prepare for the application process, which will open in December 2025, with submissions due by February 2026. For further inquiries, potential applicants can contact Oleg Mirochnitchenko, PhD, at Oleg.mirochnitchenko@nih.gov or by phone at 301-435-0748.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)," aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that utilize well-characterized patient cohorts, infrastructure, data, and biological samples, while aligning with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). With an estimated total program funding of $600,000 and the expectation of awarding two grants, potential applicants are advised to begin developing collaborations and project proposals in advance of the official solicitation, which is expected to be published in early 2026. For further inquiries, interested parties may contact Dr. Heiyoung Park at Heiyoung.Park@nih.gov or by phone at 301-594-5032.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.